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Abstract 
A 69-year-old female presented marked 
vision loss in both eyes, intense 
photophobia and ocular pain. The patient 
had long history of uncompensated 
glaucoma, Graves ophtalmopathy, treated 
for several years with topical medication 
without normalizing the intraocular 
pressure. The patient undergo orbital 
decompression for Grave’s ophtalmopathy 
which ameliorated the exophthalmia.  
Visual assessment showed 0,08 best 
corrected visual acuity (BCVA) in the right 
eye respectively 0 in the left eye, posterior 
chamber pseudophakic implant both eyes, 
posterior capsular opacification left eye. 
The intraocular pressure was 18-25 mmHg 
in the right eye, respectively 14-19 mm Hg 
under topical medication. The cup-disc 
ratio was 0.8 in the RE respectively 0.9-1 in 
the LE. The visual field assessment in the 
RE showed relative central scotoma, 
complete lower arcuate (Bjerrum) scotoma, 
generalized depresion of VF. We performed 
RE trabeculectomy with  5 fluorouracil and 
collagen implant (OLOGEN®), with good 
postoperative evolution. The Visual Acuity 
improves significantly to 0.1, the IOP after 
a month was 15 mm Hg. The onset, 
symptomatology and general clinical 
context of the patient determined the focus 
on the neuro-ophthalmological aspect of 
the case, even if that meant that the control 
of the glaucoma, at times obviously 
inefficient, would remain second, from the 
perspective of its importance.  
Keywords: combined mechanism 
glaucoma, compressive ischemic optic 
neuropathy, Grave's orbitopathy, collagen 
implant. 
 
Thyroid orbitopathy is an 
immunological disorder that affects the 
orbital muscles and fat. Hyperthyroidism is 
seen with orbitopathy at some point in 
most patients, although the two are 
commonly asynchronous. Middle-aged 
adults (30–50 years) are affected most 
frequently, the disease is seen in women 
more commonly than in men, in a ratio of 
3-4:1, it is always a bilateral process but is 
often asymmetrical and multiple muscles 
are involved simultaneously, most 
commonly the inferior and medial 
rectus.[10] 
Symptoms and signs include dry eyes, 
conjunctival injection, lid retraction, 
exophthalmos, diplopia, corneal exposure, 
and rarely optic nerve compression. Graves’ 
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disease usually runs a progressive course for 
3–5 years and then stabilizes. 
Primary open angle glaucoma is 
associated with Graves ophthalmopathy 
(GO) in 5-24% of the cases. There are 
studies who support the association of GO 
with normal tension glaucoma.  
Case report 
A 69-year-old female presented marked 
vision loss in both eyes, intense 
photophobia and ocular pain. 
The history shows that the patient was 
diagnosed in May 2001 with 
hypothyroidism, treated with 
levothyroxinum (Eutirox®). In march 2003 
she presented with signs of exophthalmia, 
the analyses certified the Hyperthyroidism. 
In may 2003 the patient complained of 
visual loss in left eye (LE), over a two 
month period associated with moderate 
exophthalmia, visual loss in right eye (RE) 
with slower progression. 
In July 2003 the patient was diagnosed 
with Basedow Grave’s disease and thyroid 
ophthalmopathy. The visual assessment 
showed best corrected visual acuity (BCVA) 
0.04 in the RE, respectively hand motion 
(HM) in the LE. The computer-
tomography: bilateral exophthalmia with 
hypertrophy of ocular extrinsic muscles and 
infiltration of the retrobulbar fat tissue. The 
intraocular pressure (IOP) was 30 mm Hg 
in both eyes. The ophtalmoscopy revealed 
precise contour optic disk with normal 
coloration. The patient presented marked 
ophtalmoplegia with extremely limited 
ocular motility. The patient was 
recommended Latanoprostum, 
Brinzolamide and Timolol (Xalatan®, 
Azopt® and Timolol®). For the Thyroid 
Ophthalmopaty the patient received 
repeated Methylprednisolone therapy 
(SoluMedrol®). 
In September 2003, the patient with 
Basedow Grave’s disease was treated with 
antithyroid drugs, the BCVA was 0.04, 
respectively HM. The IOP remained 30 
mm Hg even under topical medication: 
Latanoprostum, Brinzolamide and Timolol 
(Xalatan®, Azopt® and Timolol®). 
In October 2003 for marked visual loss 
and following the CT scan which revealed 
marked optic nerve tumefaction at the level 
of the bilateral optic channel, the patient 
undergo surgery treatment, RE 
decompression of the optic nerve in the 
optic channel and orbital fat resection, 
which led to the amelioration of 
exophthalmia. In November 2003, the 
follow-up mentions “a slight sight 
improvement”, without specifying any 
particular values, after the serious sight 
aggravation, immediately after the surgery. 
In February 2004 the patient’s 
diagnostics were malignant Basedow 
Grave’s disease, Grave’s ophtalmopathy, 
compensated glaucoma both eyes, optic 
atrophy, left eye total optic atrophy, 
incipient cortisone cataract both eyes, 
iatrogenic Cushing’s syndrome, diabetes 
mellitus, dyslipidemic syndrome. The 
visual assessment showed the BCVA 0.06, 
in the RE respectively no perception of 
light (NPL) in the LE. The IOP was 18 
mm Hg, respectively 19 mm Hg under 
treatment with Latanoprostum, 
Brinzolamide and Timolol (Xalatan®, 
Azopt® and Timolol®). The 
ophthalmoscopy revealed discolored, 
moderately swollen optic disks, no cupping. 
The visual field (VF) assessment showed 
isolated areas of light sensitivity in the 300 
central area. This seems to be a glaucoma 
via orbital compression: Latanoprostum 
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(Xalatan®) is no longer used for the 
treatment. The IOP continues to be treated 
with Timolol and Brinzolamide (Timolol® 
and Azopt®), remaining at the same values. 
The general recommended treatment was 
Piracetam® and Difrarel®. 
In March 2004, the BCVA was 0.016, 
the IOP 19-20 mm Hg under Timolol and 
Brinzolamide (Timolol® and Azopt®), 
constriction of the visual field. One tablet 
of Acetazolamidum (Ederen®) and two 
tablets of Nicergoline (Sermion®) were 
added. The MRI exam revealed muscular 
hypertrophy, more important in the 
posterior half of the muscular body, at 
which level the optic nerves are compressed 
in their trajectory to apex of orbit. 
In June 2004, the BCVA was 0.033 and 
NPL, the IOP 17-31 mm Hg under 
Timolol and Brinzolamide (Timolol® and 
Azopt®). An interdisciplinary examination 
concluded that this is a compression 
glaucoma (“Pseudo-glaucoma”), for which 
the recommended treatment is: 
Acetazolamidum, Timolol and 
Brinzolamide (Ederen®, Timolol®, 
Azopt®), Prednisone 80mg/day for 3 
weeks, after which the dose will be 
decreased.  
In August 2004 the right eye cataract 
undergo surgery, was performed 
phacoemulsification with posterior 
chamber pseudophakic implant (PC IOL), 
with favorable evolution. 
In November 2004, the patient 
presented dysthyroid orbitopathy, 
secondary glaucoma, ischemic optic 
neuropathy in both eyes, antiphospholipid 
syndrome and dyslipidemia. The patient 
continues the same treatment, with 
Timolol and Brinzolamide (Timolol®, 
Azopt®) – the IOP values are not 
measured. The MRI exam revealed optic 
nerve with reduced thickness (≈2 mm RE, 
≈1.5 mm LE); hypertrophy of the extrinsic 
muscles. The successive hospitalizations of 
April 2005, June 2005, and  July 2005 
confirm the antiphospholipid syndrome as 
being secondary to toxoplasmosis. The 
patient is under periodic treatment with 
Cerebrolysin®, Sulodexide 
(VesselDueF®). In Aprilie 2005 the patient 
was operated for cataract, with a PC 
pseudofakic  implant in the left eye. 
Over the period 2005-2008, the patient 
was treated with Cerebrolysin®, 
Sulodexide (VesselDueF®). Treatment 
with Timolol and Brinzolamide continues, 
without the monitorization of IOP. 
In May 2008 the patient was examined at 
the Rothschild Clinic. The BCVA in the 
RE was 0.02 and HM in the LE. The 
patient presented exotropia of the left eye. 
The IOP was 19 mm Hg in the right eye, 
respectively 23 mm Hg in the left eye. In 
both eyes the patient presented pseudofakic 
implant. The ophtalmoscopy revealed white 
optic disks. The visual field revealed a 
paracentral residual island, only in the right 
eye. The visual evoked potentials showed a 
persistency of a flash response in the right 
eye, a low VEP in the left eye. The OCT 
scan, performed in October 2008 revealed 
in the right eye: major optic atrophy with a 
retinal nerve fiber layer less than 50 μ 
thickness. The MRI scan showed thick and 
non-inflamed extraocular muscles in both 
eyes, with discrete compression at the level 
of the apex. 
The main conclusions at the Rothschild 
Clinic were: considering the serious nature 
of the disease and its long history, a orbital 
decompression might be useful, without a 
guaranteed favorable outcome; it is 
necessary to reduce the IOP, the 
recommended treatment was 
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Latanoprostum (Xalatan®) and 
Brinzolamide (Azopt®). Although a 
surgical orbital decompression was 
recommended, the clinic where the patient 
was hospitalized refused to perform the 
surgery. 
Over the period 2008-2009, the patient 
continues the treatment with: Sulodexide 
(VesselDueF®), Cerebrolysin® and topical 
treatment with Latanoprostum (Xalatan®), 
Dorzolamide and Timolol (Cosopt®). 
Visual discomfort becomes more intense, 
being dominated by marked photophobia. 
In November 2009 the patient was 
examined in an ambulatory department. 
The BCVA was 0.02 in the RE and NPL in 
the LE. The IOP was 40 mm Hg, in the 
right eye, respectively 24 mm Hg in the left 
eye under the treatment with 
Latanoprostum (Xalatan®), Dorzolamide 
and Timolol (Cosopt®). It was 
recommended for the patient to be 
hospitalized, and the topical treatment was 
changed with Bimatoprost and Timolol 
(Ganfort®). 
The patient arrived in our department in 
December 2009. The visual assessment 
revealed the BCVA in the right eye 0.02, 
the left eye 0 (NPL). At the slit lamp exam: 
PC pseudofakic implant in both eyes, 
posterior capsular opacification in the left 
eye. Intraocular pressure in the right eye 
was 18-25 mm Hg, respectively 14-19 mm 
Hg in the left eye (circadian curve) under 
Bimatoprost and Timolol (Ganfort®). The 
IOP correction was -1 mm Hg 
(pachymetry=551 μ, Herndon formula, 
Ocuscan RXP®) 
The gonioscopy: open angle – lower 
third degree, 2nd-3rd degree nasal and 
temporal, upper second degree. 
Ophtalmoscopy: cup-disc ratio 0.8 in the 
right eye and 0.9-1 in the left eye, choroidal  
folds at the posterior pole in the left eye. 
 
 
Figure 1 Slit lamp photo of the right eye 
 
 
Figure 2 Slit lamp photo of the left eye 
 
 
Figure 3 Fundus examination of the right eye 
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Figure 4 Fundus examination of the left eye 
 
 
Figure 5 Choroidal folds in the left eye 
 
The perimetrical assessment: the right 
visual field revealed relative central 
scotoma, complete lower arcuate (Bjerrum) 
scotoma, generalized depresion of VF. 
The general examination revealed the 
associated diseases: arterial hypertension, 
painless chronic ischemic cardiopathy, first 
degree of obesity and hypothyroidism. 
The ophthalmic diagnoses were: 
combined mechanism glaucoma both eyes, 
compressive ischemic optic neuropathy, 
optic atrophy, total left eye optic atrophy. 
We decided to perform a trabeculectomy 
with addition of 5-fluorouracil and collagen 
implant (OLOGEN™). 
Ologen™ is a biodegradable and 
implantable scaffold Collagen Matrix 
Implant. It's function is to induce a 
regenerative non-scarring wound healing 
process without the use of anti-fibrotic 
agents. The Matrix improves regeneration 
and tissue re-modeling, preventing scar 
formation. The implantation of Ologen™ is 
a simple process requiring that the 
ophthalmologist perform the operation 
based on traditional methods and 
techniques with minimal changes to suture 
techniques (such as the trabeculectomy). 
Ologen™ is implanted over the scleral flap, 
with the surgeon making sure to carefully 
suture both Tenon's capsule and 
conjunctiva over the Ologen making a 
water tight seal of the wound. 
Before surgery we maintained the ocular 
hypotonia with topical medication 
Bimatoprostum and Timolol (Ganfort®) 
and systemic osmotic Manitolum 
(Manitol®). We also began the 
neuroprotective treatment with 
Pentoxifyllinum (Pentoxifilin®) and 
Cerebrolysin®. 
The surgery consists of subconjunctival 
anaesthesia at 10-11 mm posterior to the 
limbus, we perform the lift of the 
conjunctiva. The incision is made at 9 mm 
posterior to the limbus, having a length of 9 
mm. We make a square conjuctival flap 
with the length of 9 mm. We perform a 
carefully diathermia and clean the sclera of 
any tissue (Tenon’s capsule or episclera). 
The 5 fluorouracil is then applied for 2 or 3 
minutes. After this we make the scleral flap, 
the trabeculectomy and peripheral 
iridectomy. We suture the sclera and apply 
5 fluorouracil 1 or 2 minutes. The collagen 
implant (OLOGEN ™) is implanted over 
the sclera flap with tight seal of the wound. 
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For the next day the patient wear a slightly 
compressive patch.[4] 
Immediately after the surgery the BCVA 
in the RE was 0.02, and IOP was 14-16 mm 
Hg under Dorzolamidum and Timolol 
(Cosopt®). The BCVA in the LE was 0 and 
the IOP was 17 mm Hg under Bimatoprost 
and Timolol (Ganfort®). The patient was 
administered Pentoxifyllinum and 
Cerebrolysin and, at discharge the patient 
was recommended treatment with: 
Nicergoline (Sermion®), Lutein,  Omega 3 
(Lutein-Omega 3®), and she remained 
under treatment with topic hypotensors 
(Cosopt® and Ganfort®) and also 
Indomethacin (Indocollyre®). The patient 
was treated, at home, with Cerebrosylin. 
The patient’s follow-up after a month 
revealed the BCVA in the RE 0.1. At the slit 
lamp exam: discreetly congestive filtration  
bleb, minor corneal oedema, average depth 
of the anterior chamber, free iridectomy;  
functional filtration bleb at  gonioscopy. 
The fundus exam revealed a discrete 
macular oedema. The IOP was 15 mm Hg, 
corrected with a - 4 mm Hg factor 
(pachymetry was 586 μm). The visual field 
shows extension of the deficit, with increase 
in the density of the central scotoma (aspect 
of altitudinal visiual fiel defect). 
We recommended topical treatment 
with Bimatoprost (Lumigan®), 
Indomethacin (Indocollyre®) and systemic 
treatment with Pentoxifyllinum for 10 days 
and Cerebrolysin for 5 days. 
In March 2010 the BCVA in the RE was 
0.125, the IOP 16-17 mmHg under 
treatment with  Bimatoprost (the internist 
advised against the use of Timolol because 
the patient registered cardiac side effects), a 
reduction of the density of the central 
scotoma, free central zone and reduction of 
the extension of the altitudinal VF defect.  
 
 
Figure 6 Ologen ™ Implant 
 
 
Figure 7 Slit lamp exam: filtration bleb 
 
 
Figure 8 Gonioscopy: patent filtration bleb 
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9 A 
 
9 B 
Figure 9 Visual field evolution 
 
We recommended Interruption of the 
anti-glaucoma topical medication, 
continuation of the treatment with 
Nicergoline (Sermion®) and Lutein-
Omega3®, periodical treatment with 
Cerebrolysin and Pentoxifyllinum, topical 
treatment with Indomethacin 
(Indocollyre®), if necessary, examination 
after a 3 months period. 
A. The diagnosis  
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• Combined Mechanism Glaucoma  
• Via compression 
• Primary Open Angle Glaucoma 
• Compressive Ischemic Optic 
Neuropathy 
B. The treatment  
• Medical 
• Surgical  
C. Therapeutic strategies  
• Priority of treatment of the diseases  
D. Behavior in the cases with multiple risk factors 
A. Combined mechanism Glaucoma 
It is known that the 1 mm Hg increase 
of the pressure in the episcleral veins 
determines the increase of IOP by 
approximately 1 mm. [5] Graves 
ophthalmopathy is the most frequent cause 
of obstructive mechanisms that generate the 
pressure increase in the episcleral veins. 
The IOP also increases via the pressure rise 
in the episcleral veins and via the trabecular 
blockage, through the increased deposit of 
muccopolysaccharides in the trabecular 
system. [2] The compression of the globe is 
also exercised via the fibrotic extraocular 
muscles, with increased volume, in certain 
positions of the sight. The pressure increase 
in the episcleral veins is a sure fact, for the 
MRI and the CT scans revealed 
modifications of the orbital elements 
(oculomotor muscles, orbital fat). At 
present, the LE seems to suffer from a 
certain extent of orbital compression 
(revealed by the choroidal folds at the 
posterior pole) and the eye is more 
seriously affected.  
Primary Open Angle Glaucoma 
Primary open angle glaucoma is 
associated with Graves ophthalmopathy in 
5-24% of the cases.6 There are studies who 
support the association of GO with the 
normal pressure glaucoma. [1] We thought 
about the existence of a POAG either 
simultaneously with or before the thyroid 
disease, because of the following reasons:  
- The existence of relatively high IOP 
values (even if measured with the Schotz 
tonometer) from the occurrence of the 
disease.  
- The severe decrease of visual acuity 
made us think about the preexistence of a 
disease at the level of the optic nerve.  
- We must not forget that the IOP also 
increases in GO via the trabecular blockage, 
and that the patient also suffered from 
insufficiently controlled thyroid disease, 
about 2 years before the triggering of the 
acute phenomena.  
- There is a genetically related 
predisposition between glaucoma and 
thyroid diseases.  
Counter-arguments: 
- Lack of documentation related to the 
assessment of the aspect of the optic disk 
(C/D ratio) 
- Lack of documentation related to the 
modifications of the VF 
Compresive Ischaemic Optic 
Neuropathy 
In this case, severe orbital compression 
determined, on the one hand, the increase 
of intraocular pressure, with the 
impairment of the perfusion of optic nerve 
head and on the other hand, the 
impairment of the blood flow in the orbit, 
at the level of the optic nerve. The optic 
nerve oedema may have not occurred 
following the increased values of IOP. 
Anyhow, the stasis of the axoplasmic flow 
compressed the ON in the optic channel.  
B. Treatment 
Medical treatment of glaucoma  
It seems that, in these circumstances, the 
topical medication did not manage to 
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control the evolution of the glaucoma and 
not even the IOP values. 
 
Surgical treatment of glaucoma  
The therapeutic target should have been 
established at a lower level and the surgical 
intervention should have occurred earlier. 
The surgery (in the absence of an artificial 
drainage device) was meant to be as radical 
as possible, but also safe. 
Medical treatment of Compressive Ischemic 
Optic Neuropathy  
Treatment with Cerebrolysin 
(especially) and vasodilator drugs, in 
association with Sulodexide  (not 
performed after the surgery) proved its 
efficiency. The sustained neuroprotective 
treatment contributed to the post-operative 
improvement of VA and VF. We consider 
that such a neuroprotective treatment is of 
great interest in all the diseases that target 
the ON, either directly or indirectly. Anti-
edematous treatment with intravenous 
Acetazolamide would have also been useful.  
Surgical treatment of compressive ischemic 
optic neuropathy 
The first decompression had a relatively 
limited effect. The intervention was the 
only viable solution in the given situation. 
The subsequent evolution of the disease 
seems to have shown that a second 
decompression would have not had better 
results. This was also the decision of the 
neurosurgeons that were requested to 
perform a second intervention. We must 
underline the importance of 
neuroprotective medication as adjuvant 
therapy in all these situations. 
C.  Therapeutic strategies  
We consider that an equidistant 
approach of the components of eye 
impairment would have been appropriate in 
this case. If, in the case of the ON, the 
surgical intervention was choosen hastily, 
maybe this is how it should have with the 
glaucoma. There may have been constraints 
as concerns the decision of performing the 
glaucoma surgical intervention, associated 
with the discovery and exposure of the 
filtration bleb because of the exophthalmia; 
an artificial drainage system would 
definitely have been a good solution at any 
given time. The modest result of the 
laminectomy may have reduced the hopes, 
associated with the benefits of glaucoma 
surgery.  
D. Behavior in the cases with multiple 
risk factors 
- Analysis of each disease, with the 
evaluation of the impact on the target 
segments.  
- Analysis of the interactions of the 
diseases and of the most exposed areas 
following the combined action of risk 
factors.  
- Overall analysis of the general 
etiopathogenic context. 
Conclusions 
The open-angle glaucomas are chronic, 
progressive optic neuropathies, that have in 
common characteristic morphological 
changes at the optic nerve head and retinal 
nerve fibre layer in the absence of other 
ocular disease or congenital anomalies. 
Progressive retinal ganglion cells death and 
visual field loss are associated with these 
changes. [8,9] 
It is much easier to make accurate 
assessment by analyzing at the end, a long 
sequence of data and information that 
become complete and clear, along the way.  
Unfortunately, most of the times we 
have to choose the best solution at that very 
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moment and we can only hope that there 
will be only few cases, when this solution 
does not turn out to be the best. 
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